These findings highlight the potential therapeutic benefit of the combination of Twist1 blockade with vorinostat in the treatment of pancreatic cancer, clearly showing that it has a stronger effect in suppressing cell migration. This evidence concerns the gene TWIST1 and familial pancreatic carcinoma.